DeutschNewstral
Article
bizjournals.com on 2019-01-04 17:18
Biogen doubles down on Alzheimer's with new collaboration deal
Related news
- Denali shares soar on potential $2.4 billion Parkinson's, Alzheimer's deal with Biogenbizjournals.com
- Biogen down in premarket trading after newest Alzheimer's drug trial resultsbizjournals.com
- BBiogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy3 min readbarrons.com
Biogen CEO to Step Downwsj.com
Biogen trial drug shows promise in fight against Alzheimer'sThe Japan Times- Biogen pays California biotech $350M upfront for Alzheimer's gene therapybizjournals.com
- WAlzheimer's drug from Biogen, partner receives FDA approvalwraltechwire.com
- Biogen analysts pounce on 'thin' Alzheimer's trial databizjournals.com
Biogen says new drug shows promise in combating Alzheimer'smetro.us- Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conferencebizjournals.com
Biogen shares soar as FDA reviewers support Alzheimer's drugSydney Morning Herald- Biogen buoyed despite Alzheimer's drug's new, more restrictive labelbizjournals.com
Biogen to cease production of controversial Alzheimer's drugPOLITICO- Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drugbizjournals.com
- Biogen lays out plans for confirmatory study of Alzheimer's drugbizjournals.com
- Biogen reworks Alzheimer's drug pacts in bullish movebizjournals.com
- Biogen stock gains on leaked Alzheimer's drug databizjournals.com
- In reversal, Biogen to file for approval of Alzheimer's drugbizjournals.com